Amgen Inc. (AMGN )

Currency in USD Disclaimer

$302.13 -$7.73 (-2.49%)

Open 04/04/2025

Day's Range

$301.43

$312.11

52 wk Range

$253.3

$346.85

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Symbol AMGN
Company Amgen Inc.
Price $302.13
Changes Percentage -2.49
Change -7.725
Day Low $301.43
Day High $312.11
Year High $346.85
Year Low $253.3
Market Cap $164,465,310,750
Price Avg 50 EMA (D) $303.53
Price Avg 200 EMA (D) $306.84
Exchange NASDAQ
Volume 1,433,243
Average Volume 3,245,231
Open $312.11
Previous Close $309.85
EPS 7.55
PE 40.55
Earnings Announcement 2025-05-01 20:00:00
Shares Outstanding $537,205,000

Company brief: AMGEN INC. (AMGN )

Sector Healthcare
Industry Drug Manufacturers - General
CEO Mr. Robert A. Bradway
Website https://www.amgen.com
Headquarters US
Employees (FY) N/A
Founded 06-17-1983
ISIN US0311621009

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.